Taking into account all of the above and given that the use of PARP-1 inhibitors has been linked to resistance after a period of treatment, the use of selective inhibitors of iNOS could be considered in cases of high PARP-1 expression and also those harboring wild-type p53 in CRC. This evidence concerns the gene PARP1 and colorectal carcinoma.